New treatments to improve memory in Alzheimer's disease
Official title: Development of Novel Small molecule modulators of synaptic plasticity for the treatment of AD-induced cognitive decline
Funded at Encue INC. · NIH-11007127 · Data updated 2026-11-12
This study is testing a new medication called JB2 to see if it can help improve memory and learning by boosting brain health in people with early Alzheimer's disease.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Encue INC. NIH-funded |
| Lab location | 1 site (Evanston, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $499,998 |
| NIH project number | 1R43AG087761-01A1 |
| Project ID | NIH-11007127 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage Alzheimer's disease who are experiencing cognitive decline.
✕Less likely to help
Patients with advanced Alzheimer's disease or those with other forms of dementia may not benefit from this research.
What this research studies
This research focuses on developing a new small molecule, JB2, that aims to enhance synaptic plasticity, which is crucial for learning and memory. By targeting the insulin-like growth factor 2 receptor (IGF2R), JB2 seeks to restore synaptic health in the early stages of Alzheimer's disease (AD). The approach involves understanding how JB2 can activate specific receptors in the brain to improve cognitive function and potentially slow down the progression of AD. Patients may be monitored for changes in memory and cognitive abilities as part of the research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve memory and cognitive function in patients with Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in enhancing synaptic plasticity as a therapeutic target for Alzheimer's disease, suggesting potential for success with this novel approach.
Where this research is happening
-
Encue INC.
Evanston, United States Active
Researchers
- Principal investigator: Loffler, Alicia — Encue INC.
- Study coordinator: Loffler, Alicia
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Optimizing a closed-loop digital meditation to help cognitive aging and stress in older adults
A mobile, personalized meditation program is being tested to help older adults maintain thinking skills and lower stress.
-
Cash transfers in South Africa to reduce dementia risk in later life
This project tests whether government cash transfers in rural South Africa help protect people’s thinking and memory as they age.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.